分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Molecular analyses of prostate tumors for diagnosis of malignancy on fine-needle aspiration biopsies

Menglin Shan, Qianlin Xia, Dong Yan, Yanjun Zhu, Xuan Zhang, Guihong Zhang, Jianming Guo, Jun Hou, Weiping Chen, Tongyu Zhu, Xiaoyan Zhang, Jianqing Xu, Jin Wang, Tao Ding, Jianghua Zheng

Journal:Oncotarget

IF:5.17

DOI:10.18632/oncotarget.22289

PMID:

Published:2017-11-06

research field:肿瘤学分子生物学诊断医学

Abstract

Prostate cancer (PCa) is a common cancer and remains the second-leading cause of cancer-associated mortality in men, but diagnosis of PCa remains a main clinical challenge. To investigate the involvement of differentially expressing genes in PCa with deregulated pathways to allow earlier diagnosis of the disease, transcriptomic analyses of differential expression genes in fine-needle aspiration (FNA) biopsies helped to discriminate PCa from benign prostatic hyperplasia (BPH). We identified 255 genes that were deregulated in prostate tumors compared with BPH tissues. qRT-PCR was conducted to examine the expression levels of the four genes in FNA biopsies and confirmed that ITGBL1 was significantly up-regulated and HOXA7, KRT15 and TGM4 were down-regulated in the PCa compared to the BPH, with a sensitivity of 87.1% and a specificity of 87.8%; the area under the receiver operating characteristic curve was estimated at 0.94, which was significantly improved compared with PSA alone (AUC = 0.82). Moreover, the increased expression of ITGBL1 correlated with total cholesterol, triglyceride and PSA. Our results demonstrated that transcriptomic analyses in FNA biopsies could facilitate rapid identification of potential targets for therapy and diagnosis of PCa.

本文使用的Yeasen产品

购物车
客服
转染试用